<DOC>
	<DOCNO>NCT02713672</DOCNO>
	<brief_summary>The cytochrome P450 ( CYP ) group metabolic enzymes , 2D6 CYP2C19 polymorphism specifically related metabolism psychiatric drug . The prevalence CYP2D6 CYP2C19 polymorphisms differs among ethnicity . Depending number functional allele , individual classify Poor Metabolizer ( PM ) , Intermediate Metabolizer ( IM ) , Extensive Metabolizer ( EM ) Ultra Rapid Metabolizer ( UM ) . Research suggest PM genotype predispose factor antipsychotic-induced side-effects . Besides susceptibility side effect low quality life , also , relationship phenotype cost care show . Guidelines recommend PM , IM UM genotype need dose adjustment , optimize effectiveness drug and/or reduce side effect . No research do investigate cost-effectiveness implementation genotyping daily clinical psychiatric practice . This study investigate effectiveness implementation CYP2D6 CYP2C19 genotyping psychiatric patient Curacao analyze cost genotyping versus health benefit .</brief_summary>
	<brief_title>Cost-effectiveness CYP2D6 CYP2C19 Genotyping Psychiatric Patients Curacao</brief_title>
	<detailed_description>Subjects This study carry Caribbean island Curacao Netherlands . The population ( approx . 150,000 inhabitant ) Curacao mainly Negroid descent . Participants recruit Klinika Capriles , ( psychiatric hospital island ) psychiatric ward prison ( FOBA ) psychiatric polyclinic island ( Psychiaters Maatschap Antillen ) . The study protocol approve Medical Ethical Review Board ( Maastricht ) study participant give write informed consent explanation study . Inclusion criterion : ( ) An Antillean ethnicity , define line Dutch Central Bureau Statistics birth former Dutch Antilles birth least one parent former Dutch Antilles . ( ii ) Age 18 year old . ( iii ) The use antipsychotic antidepressant ( iv ) inform consent . All patient genotyped grouped accord predict phenotype CYP2D6 CYP2C19 . Information medication use collect . Patients use CYP2D6 CYP2C19 inhibit medication accord Flockhart select . Enzyme activity score patient use strong inhibitor multiply 0 meant convert automatically PM phenotype . In patient use medium inhibitor , activity score multiply 0.5 . This widely use accept method . All prescribed antipsychotic calculate `` Defined Daily Dose '' ( DDD ) define World Health Organization ( WHO ) . For every patient total equivalent DDD calculate . In way possible analyse difference total dose antipsychotic use phenotype group . Patients need dose adjustment base phenotype accord Royal Dutch Association Advancement Pharmacy select . Patients select matched control gender , age depot oral medication use . All participant receive 25 guilder gift token cooperate study measure point . Assessments Subjective experience , psychopathology , extrapyramidal side effect , quality life , global functioning metabolic parameter assess baseline ( T0 ) 4 month dose adjustment ( T1 ) . A medical doctor , trainee psychiatry , blind intervention , responsible measurement train investigate extra pyramidal side effect measure global functioning . Patients receive depot medication measure moment depot T0 T1 . Severity patient ' psychopathology assess Brief Psychiatric Rating Scale ( BPRS ) , measure 24 symptom psychiatric disease validate Dutch 20 . Extrapyramidal symptom assess St. Hans Ratings Scale ( SHRS ) , multidimensional rating scale evaluation hyperkinesia , parkinsonism , akathisia dystonia induce neuroleptic . The dyskinesia score two situation : passive active circumstance . Akathisia measure Barnes Rating Scale ( BARS ) Drug-Induced Akathisia . Subjective experience patient measure Subjective Well-Being Under Neuroleptics Scale ( SWN-20 ) , 20- item , self-rating scale ass subjective experience precede 7 day . Quality life assess EurolQol 5-D ( EQ 5-D ) , widely use rating scale , measure health status five dimension ( mobility , self-care , usual activity , pain/discomfort anxiety/depression ) . Global functioning assess World Health Organization Disability Assessment Schedule 2.0 ( WHODAS-36 ) 36 item proxy-administered version . The questionnaire measure disability 6 domain administer personal care giver . Metabolic parameter measure blood pressure , Body Mass Index ( BMI ) , waist size , cholesterol , High Density Lipo-protein ( HDL ) , Low Density Lipo-protein ( LDL ) , triglyceride , glucose , Hemoglobin A1c ( HbA1C ) . Prolactin also measure . In patient receive antipsychotic metabolize CYP2D6 , plasma level antipsychotic measure . Procedures After baseline measurement , another medical doctor , trainee psychiatry make dose adjustment accord guideline Royal Dutch Association Advancement Pharmacy ( KNMP ) update July 2013 . Generally three option available : 1 . Lowering/ enhance dose 50-75 % original dose 2 . Prescription medication metabolize CYP2D6 CYP2C19 3 . Stop CYP2D6 CYP2C19 inhibit medication . A standard procedure dose adjustment follow : Lowering dose do step accord http : //wiki.psychiatrienet.nl/index.php/SwitchAntipsychotics . If alternative antipsychotic prescribed , first choice flupentixol , second choice olanzapine , third choice quetiapine . Inhibiting medication mean tranquilize replace benzodiazepine . Complex case discuss research team individual dose adjustment plan make .</detailed_description>
	<criteria>1 . Antillean ethnicity , define line Dutch Central Bureau Statistics birth former Dutch Antilles birth least one parent former Dutch Antilles 2. age 18 year old 3. use antipsychotic antidepressant drug 4. write informed consent . 1 ) inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>